AIMD Company Profile and Key Details

AIMD has shown mixed momentum, losing -1.05% over the past week and -52.64% over the past quarter, though year-to-date performance is up 14.63%. Short-term trend indicators are bullishly aligned (SMA20 -5.01%, SMA50 -9.72%, SMA200 -39.83%). The stock’s 14-day RSI is 47.6 (neutral), while the ATR of 0.19 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -63.11% below its high and over 31.75% above its low. Average 10-day trading volume of 38.80 thousand shares is below the 3-month average of 670.11 thousand, indicating normal recent market interest.

Ainos, Inc. generated EPS of -$4.18 over the past year. Five-year average earnings growth is 12.06%.

Ainos, Inc. has 6.98 million shares outstanding. The public float is 2.15 million shares, elevated short interest at 3.32% of float. This equals 99.13 thousand shares. The short ratio is 0.06 days. Institutional investors hold 7.96% of the float. Insiders own 65.53%. AINOS INC holds 12.93 million shares, chang wen-han has 4.00 million shares and lee ting-chuan has 1.43 million shares. Over the past six months, insider transactions show net selling. They sold 58.99 thousand shares across 7 transactions.

Ainos, Inc. (NASDAQ:AIMD) closed at $1.38 USD, losing -$0.09 (-6.12%) from the previous close of $1.47. The stock is currently mid-range between its 52-week high and low $1.26 and $4.50. With a market capitalization of about $6.65 million, Ainos, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.33). Key stats such as the average daily volume over the past year has been around 659.95 thousand shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Ainos, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Chun-Hsien Tsai, the company employs approximately 44 people and listed since January 08, 2021. Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications.

Our AI price prediction model suggests that Ainos, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -11.59%, with price expected at $1.22 by March 20, 2026, within a range of $0.96 to $1.49 3-Month Outlook: Projected fall of -23.91%, reaching $1.05 by June 01, 2026, with a range of $0.92 to $1.17. 1-Year Outlook: Projected gain of 10.87%, with price at $1.53 by March 05, 2027, within a range of $0.88 to $2.06.

Ainos, Inc. (NASDAQ:AIMD) shares are up 14.63% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Ainos, Inc. trading at a premium to the broader market with a P/E of -0.42. Our AI forecast model points to short-term weakness (-11.59% over two weeks), a medium-term fall (-23.91% over three months), and a longer-term gain (10.87% over one year), with expected trading ranges indicating moderate volatility.

Ainos, Inc. trades at a P/E ratio of -0.42, slightly below the S&P 500 average, with a price-to-sales ratio of 59.29 and a price-to-book ratio of 0.63 suggesting the stock is closer to book value. The P/FCF stands at -1.44, also below market averages.

Ainos, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.90. This means the shares are trading below this model’s fair value.